START- STRATEGIC TIMING OF ANTIRETROVIRAL THERAPY

开始——抗逆转录病毒治疗的战略时机

• 批准号: 8166579
• 负责人: DANIEL W NIXON
• 金额: $ 0.07万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166579
• 关键词: Acquired Immunodeficiency Syndrome; Adverse event; Aspirin; Bacterial Pneumonia; Blood Pressure; Caring; Cessation of life; Computer Retrieval of Information on Scientific Projects Database; Congestive Heart Failure; Coronary; Coronary Arteriosclerosis; Deep Vein Thrombosis; Development; Diabetes Mellitus; Dialysis procedure; Electrocardiogram; End stage renal failure; Funding; Grant; HIV; HIV drug resistance; Hospitalization; Institution; Kidney Transplantation; Lipids; Liver diseases; Malignant Neoplasms; Myocardial Infarction; Outcome; Peripheral arterial disease; Pharmaceutical Preparations; Proteinuria; Protocols documentation; Pulmonary Embolism; Quality of life; Research; Research Personnel; Resources; Risk Behaviors; Skin Cancer; Source; Squamous Cell; Stroke; Time; United States National Institutes of Health; antiretroviral therapy; blood lipid; cost; health care service utilization; mortality; secondary outcome; transmission process

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this protocol is to determine whether early ART is superior to deferred ART in delaying the occurrence of a composite outcome consisting of HIV-AIDS, non-AIDS, or death from any cause. Secondary Objectives include: a. To compare early ART to deferred ART for each component of the primary composite endpoint: ¿ AIDS or death from AIDS ¿ Non-AIDS or death not attributable to AIDS b. To compare early ART to deferred ART for the following secondary outcomes: ¿ All-cause mortality ¿ Non-AIDS ¿ CVD (myocardial infarction, stroke, coronary revascularizaton) ¿ ESRD (initiation of dialysis, renal transplantation) ¿ Decompensated liver disease ¿ Non-AIDS malignancy, excluding basal and squamous cell skin cancers ¿ Non-AIDS malignancy, including basal and squamous cell skin cancers ¿ AIDS ¿ Bacterial pneumonia ¿ Adverse events ¿ Hospitalization ¿ Quality of life ¿ Health-care utilization and cost of care ¿ HIV transmission risk behavior ¿ HIV drug resistance ¿ Pulmonary embolism or deep vein thrombosis ¿ New-onset diabetes mellitus ¿ Coronary artery disease requiring drug treatment ¿ Congestive heart failure ¿ Peripheral arterial disease ¿ Change in estimated GFR and development of proteinuria ¿ Blood pressure and blood lipids ¿ ECG abnormalities ¿ Use of blood pressure- or lipid-lowering treatment or aspirin

该副本是使用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这是调查员的机构。 该方案的主要目的是确定早期艺术在延迟复合结果时是否优于递延艺术 由艾滋病毒，非辅助或死亡的任何原因组成。 次要目标包括： 一个。比较早期的艺术以推迟主要复合终点的每个组成部分： „艾滋病艾滋病或死亡 �非辅助或死亡不是艾滋病 b。比较早期艺术以推迟艺术的以下次要结果： »全因死亡率 非辅助 CVD（心肌梗塞，中风，冠状动脉血管造成） ESRD（透析的启动，肾移植） »肝脏疾病不足 »非AIDS恶性肿瘤，不包括碱性和鳞状细胞皮肤癌 »非AIDS恶性肿瘤，包括碱性和鳞状细胞皮肤癌 艾滋病 细菌性肺炎 不良事件 住院 »生活质量 „医疗保健利用和护理成本 »HIV传播风险行为 »HIV耐药性 „肺栓塞或深静脉血栓形成 新的糖尿病 „需要药物治疗的冠状动脉疾病 �充血性心力衰竭 �周围动脉疾病 »估计GFR的变化和蛋白尿的发展 »血压和血脂 ECG异常 »使用血压或降脂治疗或阿司匹林